Chapter 3
Current Guidance on the Use of Human Biological Materials in Research

In the United States, the current landscape of oversight affecting the use of human biological samples in research includes existing federal regulations, state statutes governing privacy and research use of medical records, policies developed by domestic scientific and professional societies, and guidelines developed by other countries and international organizations.

When NBAC began its review of the use of human biological materials in research, the work of a number of organizations provided a useful understanding of the range of positions that exist among those that have carefully considered this subject. This chapter summarizes the current existing federal regulations\(^24\) and how the practice of IRB review and informed consent might be viewed when considering the ethical research use of human biological materials. (The regulations are also reproduced in Appendix A of this report.) It also provides a synopsis of the status of the debate over privacy of medical information, and outlines existing policies regarding research use of human biological materials developed by scientific and medical organizations, both domestically and internationally.

Scope of the Current Federal Regulations

The Federal Policy for the Protection of Human Subjects (45 CFR 46, or the “Common Rule” as it is sometimes called) was promulgated by 17 federal agencies that conduct, support, or otherwise regulate human subjects research; the Food and Drug Administration (FDA) also adopted certain provisions of the Common Rule. The FDA also is governed by additional regulations that apply to research on products in its regulatory purview.\(^25\) As is implied by its title,\(^24\) As used in this report, the term “federal regulations” refers to the Department of Health and Human Services regulations contained in Part 46 of Title 45 of the Code of Federal Regulations, except where noted.\(^25\) In addition, on February 28, 1997, FDA announced a Proposed Approach to Regulation of Cellular and Tissue-Based Products [Docket Number 97N-0068], which encompasses an array of medical products derived from the human body and used for replacement, reproductive, or therapeutic purposes. The document is available at
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

the Common Rule is designed to make uniform the human subjects protection system in all relevant federal departments and agencies. The NIH Office for Protection from Research Risks (OPRR) has taken the lead within the Federal Government on the task of harmonizing human subjects protections across agencies.26

When the federal regulations are applied to research using human biological materials, a series of initial inquiries is needed to determine whether the regulations apply at all.

1. Does the activity constitute research?

The federal regulations do not apply to purely clinical interventions, even if they are outside the commonly accepted practices. Rather, they apply to research, defined as “a systematic investigation designed to develop or contribute to generalizable knowledge” (46.102(d)). If the use of the materials occurs solely as a part of clinical intervention, as might be the case in a pathology laboratory, then the federal regulations do not apply. Use of materials that has both a clinical and a research component, however, might be subject to the federal regulations (see #2 below). Thus, if a pathology laboratory saves some tissue left over from a clinical intervention to do further, research-oriented testing that research would be subject to the federal regulations.

www.fda.gov/cber/gdlns/celltissue.txt.

26 The Office for Protection from Research Risks (OPRR) fulfills responsibilities set forth in the Public Health Service Act. These include: (1) Developing and monitoring, as well as exercising compliance oversight relative to: (a) HHS Regulations for the protection of human subjects in research conducted or supported by any component of the Department of Health and Human Services; and (b) PHS Policy on Humane Care and Use of Laboratory Animals involved in research conducted or supported by any component of the Public Health Service; (2) coordinating appropriate HHS regulations, policies, and procedures both within HHS and in coordination with other Departments and Agencies in the Federal Government; and establishing criteria for and negotiation of Assurances of Compliance with institutions engaged in HHS-conducted or supported research involving human subjects and those engaged in PHS-conducted or supported research using animals; (3) conducting programs of clarification and guidance for both the Federal and non-Federal sectors with respect to the involvement of humans and the use of animals in research; and directing the development and implementation of educational and instructional programs and generating educational resource materials; 4) evaluating the effectiveness of HHS policies and programs for the protection of human subjects and the humane care and use of laboratory animals; and (5) serving as liaison to Presidential, Departmental, Congressional, interagency, and non-governmental Commissions and Boards established to examine ethical issues in medicine and research and exercises leadership in identifying and addressing such ethical issues.
2. Is the research subject to federal regulation?

The federal regulations apply only to research supported by funding from one of the federal agencies subscribing to the Common Rule or research conducted at an institution or by an individual investigator at that institution that has executed an assurance with the Federal Government stating that even research not otherwise covered by the regulations will nonetheless be governed by them. FDA regulations apply as well to research on an investigational new drug, device or biologic (21 CFR 130.2(a)(12) and (13), and 36 FR 5037).

For example, an investigator conducting privately funded research at a large university that has executed a “multiple project assurance” with the Federal Government usually will be required to abide by the federal regulations. In addition, multiple project assurance agreements include a provision that prevents researchers at that institution from evading federal regulation by conducting the research off-site or with a private, unregulated company. Instead, these multiple assurances typically promise that any researcher affiliated with the institution will abide by the federal regulations no matter where or with whom they work. Thus, research on human biological materials conducted using private funds, involving investigators who are free of affiliations with institutions that have executed a multiple project assurance, and who are not conducting research on products subject to FDA regulation, might not be subject to the federal human subjects regulations.

3. Does the research involve a “human subject”?

“Human subject” is defined by the regulations as “a living individual about whom an investigator conducting research obtains: (a) data through intervention or interaction with the individual, or (b) identifiable private information.” Specifically,
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

“Intervention includes both physical procedures by which data are gathered (for example, venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes. Interaction includes communication or interpersonal contact between investigator and subject. Private information includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). Private information must be individually identifiable (i.e., the identity of the subject is or may readily be ascertained by the investigator or associated with the information) in order for obtaining the information to constitute research involving human subjects.” (46.102(f)(1)&(2))

From this definition it is apparent that an investigator who interacts with a person to obtain a new blood or saliva sample is doing human subjects research, regardless of whether the investigator records any personal information about the subject.

When working with existing stores of biological materials, an investigator is defined as doing research on a “human subject” when he or she obtains “identifiable private information.” Section 46.102(f)(2) defines “identifiable” to mean “the identity of the subject is or may readily be ascertained by the investigator or…. associated with the information.” OPRR interprets “identifiable” to include samples with codes that, with the cooperation of others, could be broken in order to reveal the name of the tissue source. On the other hand, according to the regulations, research on samples provided to the investigator with no personal identifiers and where no codes linked to personal identifiers are maintained would not be covered by the regulations because no human subject would be involved. This provision has been the cause of some confusion on the part of the research community. According to the regulations, research on samples that are

Agreement.

Personal communication from Dr. Gary B. Ellis, Director, OPRR, April 8, 1998.
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

linked, even through a code, to personal information about the tissue source constitutes research on a human subject and is subject to the federal regulations.

For example, imagine a researcher interested in doing basic work toward the development of the mapping and sequencing of the human genome. He or she might request tissue samples from a repository that has stored specimens from an entire kindred. The samples are identified by position within the kindred (e.g., “father”, “daughter,” “maternal aunt”), but the identity of the family was never recorded at the time the samples were collected. Thus, even if the investigator and the repository were to attempt to recontact the tissue donors, it would be impossible, because their identities are entirely unknown. In this scenario, according to the regulations, there would be no human subject of research involved; no IRB review would be necessary, nor would consent from the tissue donors for new and unanticipated forms of research be required. If, however, means were developed to link this material to particular individuals, the use of these samples would, under federal regulations, become human subjects research.

A different situation develops when tissues are identified in the human biological materials collection but the identifiers are stripped before release to an investigator. Imagine, for example, that an institution called HBM Collection of America ("CoA") has a number of tissues from kindreds. Investigator Smith requests samples from a family with achondroplasia (dwarfism). CoA takes samples from Family Jones, strips all references to the family name “Jones,” and supplies them to the investigator marked only by position within the family group, for example, “father,” “mother,” “maternal aunt,” or “son.” The investigator has no way of knowing that the samples come from the Family Jones, and thinks of the samples as unidentifiable. If CoA has not kept a record linking the samples to Family Jones, then, according to the regulations, no human subject is involved in the investigator's research on the samples, and no IRB review or informed consent is required. However, if CoA has kept a record that it sent “Family Jones”—and only Family Jones—to the investigator, then, in fact, the identity of each tissue source can be nearly or completely reconstructed by combining what the investigator
knows (family position) with what CoA knows (name of family). The federal regulations are somewhat ambiguous as to whether this meets the regulatory definition of “identifiable,” although it appears that it would. Keeping in mind that one of the reasons for being concerned with identifiability of the family is to assess the possibility that research information could flow back to the tissue source, this scenario appears to describe a situation in which information could be linked between the investigator and a particular member of family (with some added difficulty if there is more than one maternal aunt or son).

Even more complex than the scenario just described is if CoA provides samples from several family groups, e.g. Family Jones, Family Smith, and Family Williams. In this situation, no individual tissue source can be determined with precision, but each individual can be identified as part of the small group that makes up these three families. If the investigator were to provisionally discover that samples from one of the families provided by CoA indicated that its sources were at some risk of significant illness, there could certainly be a temptation to send this ambiguous but possibly useful information back to the sources via CoA’s record of which family’s samples were under study. With respect to current federal regulations, however, it is not clear whether such a research protocol would be considered human subject research.

Finally, under current federal regulations, only living individuals can be human subjects. Research involving tissues from individuals who are deceased at the time of the research is not subject to the Common Rule, regardless of whether or not prior informed consent was obtained. Such research may, however, be subject to the requirements of applicable state law. Of course, there may be ethical concerns regarding the use of such tissues beyond the scope of current law or regulation. In addition, where research using samples from deceased individuals involves identifiable private information about their living relatives, those relatives may themselves be “human subjects” under the federal regulations and must be afforded all required protections. Indeed, certain types of genetic research or research on families could pose risks for living relatives of the deceased (DeRenzo, 1997).
For example, if research was conducted on autopsy material of a 30-year-old woman who died in a traffic accident, and it was inadvertently found and disclosed that she possessed the gene for Huntington’s disease (which might not become manifest until age 50), then that woman’s children automatically move into a high-risk category for Huntington’s disease. Were they to be informed of this finding they would then face the prospects of being tested, coping with the psychosocial aspects of being at risk, and face possible future health insurance and possibly employment discrimination.

4. For research requiring review, what are the IRB requirements?

For situations in which individuals who provide biological material are identifiable and, therefore, the federal regulations apply, two basic protections for human subjects generally come into play: 1) IRB review is required to ensure an acceptable balance between risks and benefits; and 2) informed consent is usually required. There are, however, exceptions and variations that are pertinent to research on human biological materials.

The twin protections of consent and IRB review might not apply if the research is found to be exempt from the federal regulations. The person given the authority to determine if an exemption applies will vary among institutions, depending upon the assurance negotiated with the government. In many cases, that person will be the chair of the research or clinical department in which the investigator works. In others, it will be the chair or the administrator of the IRB.

The regulations state that such an exemption may be applied to “research involving the collection or study of existing specimens if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects” (46.101(4)). As already noted, currently, OPRR interprets this regulation to mean that investigators who conduct research with coded samples are not eligible for the exemption if there
Informed Consent Requirements

If the research is not otherwise exempt from federal regulations as outlined above, all human subjects research generally requires consent but even in these cases this requirement can be altered or waived if certain criteria, set forth at 45 CFR, Sec. 46.116(d), are met:

1) the research involves no more than minimal risk to the subjects;
2) the waiver or alteration will not adversely affect the rights and welfare of the subjects;
3) the research could not be practicably carried out without the waiver or alteration; and
4) whenever appropriate, the subjects will be provided with additional pertinent information after participation.

The meaning of “minimal risk,” therefore, is central to determining if a non-exempt protocol is eligible for a waiver of the consent requirements. It is also a key consideration in determining whether a protocol is eligible for expedited review. In addition, the practicability of obtaining consent is an important consideration in reviewing research using human biological materials, as there might be a temporal and spatial distance between the time the material was obtained and the point at which it is used for research.

Expedited IRB Review

For research that is not exempt from IRB review and informed consent by the subject, there are nonetheless opportunities for streamlining the review process and, in some cases, obviating the need for consent. Research activities that (1) present no more than minimal risk to human subjects, and (2) involve only procedures listed in certain categories may be reviewed by the IRB through the expedited review procedure (authorized by 45 CFR 46.110 and 21 CFR 56.110).
For research on human biological materials, a key question concerning eligibility for expedited review will be whether the research poses more than a minimal risk to the subject. This assessment will depend upon the kind of information being sought in the specimen, the psychosocial and clinical significance for the subject, and the likelihood that the finding will be transmitted to the subject, or to anyone else who could associate the findings with the subject.

IRB Concern for Third-Party Interests

As mentioned previously, the federal regulations are focused on living individuals, and especially identifiable individuals. If identifiable, individuals are almost always entitled to be asked whether they wish to be a human subject of research. The IRB is asked to review a protocol to assess its risks and benefits to subjects. Nowhere in this process are the concerns of third parties explicitly taken into account.

And yet, research on one individual may reveal important, even sensitive information about others. Genetic testing on the deceased, as noted above, can yield information on living relatives. And testing on a number of otherwise unrelated individuals may yield information pertinent to many unrelated people who share salient characteristics, such as race, ethnicity, or the presence of a predisposing condition. This, in turn, could result in members of the group facing, among other things, stigmatization and discrimination in insurance and employment.

The strict focus that the federal regulations place on the interests of the individual research subject, in the view of some, can be problematic in the context of research with human biological materials. Attention should therefore be paid to considering ways in which third party interests can be considered and be protected where appropriate.

See 63 FR 60364-60367, November 9, 1998 for categories.
Imagine a hypothetical gene for a form of prostate cancer. Researchers might wish to screen large numbers of samples of prostate tissue currently stored in academic and commercial repositories to identify those with markers for the gene. Having identified this subset, investigators might then wish to examine the medical records of those men who appear to have the gene, to correlate such things as medical history, symptomology, characteristics of the tumor, treatment choices, and outcomes. This work, in turn, might result in further subsets worthy for a more refined study, to correlate the gene with a particular type of tumor or response to treatment.

Under current regulations, any link between the samples used by the researcher and the men from whom the materials were obtained would make the activity “human subjects research.” This identifiability, even if mediated by coding systems, would trigger the requirement for IRB review (at applicable institutions). The review might be eligible for expedited procedures, however, if it were deemed to be of minimal risk to the subjects and fulfilled the other requirements for expedited review.

If the initial screen of all samples, done solely for the purpose of identifying which men have the gene were done with unlinked samples, according to the regulations, the research would be exempt from IRB review. However, this would only allow for the researcher to receive a one-time, limited amount of clinical and demographic information at the time that the sample was sent from the repository. If the researcher chose to use coded samples, so as to be able to obtain follow-up information or to communicate information back to the source of the sample, the research would be subject to IRB review, even if it might still qualify as minimal risk. This might depend, in part, on the likelihood that any finding would be communicated to the individual tissue donors and whether such communications pose the risk of significant psychosocial distress.

If the research were conducted using coded samples, this would allow for a second screen.
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

in which the subset of men whose tissues show a marker for the gene would have their medical records examined. The same issues about minimal risk apply to this screen, but with a seemingly greater risk that findings will develop in the course of research that might prompt investigators to consider communicating their finding to the tissue donors or their physicians. For example, if the data strongly indicate that those with the markers respond dramatically better to one treatment than another, investigators may wonder whether it would be best to communicate this information to patients and their physicians so that the better treatment can be pursued before the patient’s health irreversibly declines.

At the same time, the tentative nature of these findings, in the view of many, may make their communication problematic. Since some prostate treatments may have significant side-effects, such as impotence and incontinence, and since the clinical data on the need to detect and treat slow-growing prostate cancers in older men is ambiguous, disclosure of such tentative findings may put patients into a position of great uncertainty and anxiety, without the assurance of clinical benefit. It is the difficulty of understanding the meaning of “minimal risk” with regard to psychosocial harm (as opposed to physical harm) that makes this issue so complex, and, in turn, makes the decision about eligibility for expedited review so difficult. It is important to note, however, that disclosures of medical information can also be beneficial to the subject. One of the primary benefits of participation in medical research is that participation might result in the receipt of health-related information, however imperfect.

Medical and Scientific Organization Standards and Guidance

When NBAC began its review of the use of human biological materials in research, it was aware that a number of scientific and medical organizations had done thoughtful work on the issue. A number of organizations developed position statements and recommendations that reflected their efforts to work through the many ethical and policy issues the topic raises. These position statements, although lacking the force of the federal regulations, can be influential in shaping the behavior and practices of the scientific community. NBAC conducted a comparative
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

Analysis of 14 statements as they applied to the issue of protections for the appropriate use of human biological materials in research. In general, there was considerable disagreement among the statements about what constitutes an identifiable human subject, when to require informed consent, and what constitutes proper consent. Confusion in the definitions, combined with vague regulatory language, has contributed to the considerable challenge IRBs face in reviewing this type of research.

8 Varying Definitions of “Identifiable”

When various scientific groups discuss “identifiable” human biological material they may mean quite different things. The four categories adopted by NBAC to describe levels of identifiability of research samples (see chapter 2)—unidentified, unlinked, coded, and identified—are described in varying terms by different groups. For example, some groups call unidentified and unlinked samples “anonymous” materials, that is, they were originally collected without identifiers or are otherwise impossible to link to their sources. Others use the phrase “anonymous use” to indicate the materials might retain identifiers in the repository but the investigator does not have access to that information.

When to Require Informed Consent and IRB Review

Many groups recommend different protections according to the degree to which samples used in a research protocol can be linked to a subject. Therefore, how a group defines identifiable information is important when considering the protections it recommends. For example, the American Society of Human Genetics (ASHG) does not use the classification “anonymous use” in its recommendations (ASHG, 1996). It does, however, discuss the appropriate use of anonymous or anonymized materials stating, “[obtaining consent] should be encouraged, except for the prospective studies in which samples are collected anonymously, or have been ‘anonymized.’”

Some groups define “identifiable” samples as exclusively “coded” materials; others use “identifiable” to encompass both “coded” and “directly identified” materials. Statements
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

developed by ASHG and the National Institutes of Health/Centers for Disease Control and Prevention (NIH/CDC) Workshop (Clayton, 1995), for example, illustrate these two uses of “identifiable.” Although ASHG differentiates between “identifiable” (meaning coded) and “identified” (meaning directly identified) samples, it recommends the same protections for both.

Likewise, the NIH/CDC Workshop does not differentiate between coded or directly identified samples when applying protections. According to the Workshop participants, even if the researcher cannot identify the source of tissue, the samples are not anonymous if some other individual or institution has this ability” (Clayton, 1995). This is consistent with current federal regulations. Accordingly, they propose, “All research that proposes to use samples that are not now or will not be made anonymous requires more thorough review.” Thus, with regard to IRB review and informed consent, coded and directly identified materials deserve equal levels of protection.

The Pathologists Consensus Statement recommends, with regard to identifiable samples, that different protections be applied to research using archived, coded samples than to research using directly identified samples. The statement emphasizes the importance and feasibility of, “maintaining patient identity and clinical information separate from research data through the use of coding” (Pathologists, 1997). In this way, they reason, the research use of coded materials does not pose the same risks to subjects as the use of directly identified materials, and does not require the same protections.

Decisions about the Appropriate Use of Existing Samples

Many organizations have provided guidelines on how to address some of the difficult decisions that arise in the course of research using stored materials. These decisions include: (1) when and how to recontact individuals regarding consent for new research uses of their samples; (2) how to judge the adequacy of previously given consent; and (3) how to assess protocols that propose to remove identifying information from samples before using them in research.
The statement from the American College of Medical Genetics (ACMG, 1995) lists factors to be considered “in deciding whether it is appropriate to use previously collected samples without contacting the individual”: “[A]re or will the samples be made anonymous?; the degree to which the burden of contacting individuals may make it impracticable to conduct research; existence and content of prior consent; and risks and benefits.”

A statement developed by the National Heart, Lung, and Blood Institute (NHLBI, 1997) lists several issues for IRBs and funding agencies to consider “[i]n judging the adequacy of a previous informed consent when an application is received to do new genetic research”: “(1) the nature of the disease proposed for study, (2) the likelihood that knowing results of the research will harm or benefit an individual, (3) the availability of effective treatment or prevention for the disorder, and (4) the burden of such treatment.”

When it is determined that it would be inappropriate to use samples without contacting individuals, the ACMG also provides guidance regarding how to recontact individuals: “Contacts regarding new research should address its purpose, limitations and possible outcomes, methods for communicating and maintaining confidentiality of results, duration of storage, uses of samples or results in studying others (anonymously), and sharing samples with other researchers for other types of research” (ACMG, 1995).

Another complex decision IRBs must address when research with stored samples is proposed involves judging the appropriateness of removing identifiers from samples. The NIH/CDC Workshop statement lists five factors for IRBs to consider “in deciding how to assess protocols that propose to make existing identifiable samples anonymous for use in research”: 1) whether the information the researcher seeks can be obtained in a manner that allows individuals to consent (this includes the possibility of using tissue samples for which people had previously given permission for use in research); (2) whether the
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

proposed investigation is scientifically sound and fulfills important needs; (3) how
difficult it would be to recontact subjects (it is not necessary, however, to prove
impracticability); (4) whether the samples are finite and, if used for research, they may no
longer be available for the clinical care of the source or his or her family (for example, use
of tumor samples may be more problematic than use of transformed permanent cell
lines); and (5) how the availability of effective medical interventions affects the
appropriateness of pursuing anonymous research (Clayton, 1995).

Collecting Samples with Appropriate Informed Consent

When collecting human biological materials from individuals in a research or clinical
setting, an informed consent process that allows individuals choices regarding how the sample
will be used after the original protocol or procedure, is an important element in the protection of
individuals’ interests and facilitation of research. Many organizations have discussed extensively
how to design a manageable informed consent process that would address the individual’s
concerns about the present and future uses of his or her sample, and is comprehensible to
patients and research subjects. The types of consent proposed ranged from general consent
(consent to future, unspecified research uses of the material), to layered consent (offers the
subject the option to consent to a variety of classes of research), to specific consent for a unique
designated protocol.

In some cases the statements offer insightful discussion regarding what level of consent is
appropriate for the use of materials. Regarding general consent, ASHG points out that in certain
instances general consent may be inappropriate, noting that “[i]t is inappropriate to ask a subject
to grant blanket consent for all future unspecified genetic research projects on any disease or in
any area if the samples are identifiable in those subsequent studies.” On the other hand, the
Pathologists Consensus Statement notes that there may be value in requiring general consent
stating, “[t]o give a description of each and every research protocol which might be performed in
the (sometimes distant) future on a patient’s tissue is an unreasonable burden for the patient and
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

Several statements advocate a form of layered consent for collecting all samples in the future. NHLBI provides thoughtful discussion on the content of a proposed three-tiered consent. In such a consent, as NHLBI describes, one is offered the option of consenting to the current study (first level), a study with goals broadly related to the area of the original study (second level), and a study with goals unrelated to the area of the original study (third level)(NHLBI, 1997).

Highlighting the importance of designing adequate informed consent mechanisms in the future, the National Action Plan on Breast Cancer National Biological Resource Banks Working Group focuses primarily on future collection and use: “The Working Group believes that when organizations with access to specimens act according to the following criteria, it should generally be unnecessary to obtain further consent from patients.” The group acknowledges that its principles apply to “prospective specimen collection,” and does not make explicit recommendations for the use of existing samples. However, these carefully developed principles can be adapted “to allow . . . pathologists to make their collections available for research and, at the same time, protect the privacy and confidentiality of the tissue sources.”

International Perspectives on the Use of Human Biological Materials in Research

Statements addressing the ethical use of human tissues in research were issued in 1998 by the European Group of Ethics (EGE) advising the European Commission, the Human Genome Organisation (HUGO), the three major funding organizations in Canada, and the World Health Organization (WHO).  

---

10 Model Consent Forms and Related Information on Tissue Banking from Routine Biopsies, Compiled by the National Action Plan on Breast Cancer Tissue Banking Working Group, with comments by the PRIM&R/ARENA Tissue Banking Working Group, 1997.

11 For a more in depth analysis of ethical and legal policy statements on the use of DNA samples in human genetic research from governmental, non-governmental and professional bodies at the international, regional and national levels, see Bartha M. Knoppers, et al “Control of DNA Samples and Information” (A report commissioned by the National Bioethics
The EGE, an advisory committee to the European Commission, issued an *Opinion on Human Tissue Banking* (1998) that covers a wide variety of human tissues used for diagnostic, therapeutic, and research purposes. In contrast to the statements issued in the United States, the opinion focuses primarily on regulating therapeutic uses of tissue (e.g., transplants), and stresses safety as an ethical imperative, calling for strict control of human tissue banks. It recommends a system that would protect the identity of the source while permitting that the source be traced if necessary to address matters of safety of the donated tissue.

The EGE Opinion also provides an overview of the status of legislation and ethical guidelines with regard to human tissue banking in the Member States of the European Union. It notes that “It is difficult to identify which institution collects and stores tissues in the Member States of the European Union and only few specific pieces of legislation exist.” In many countries legislation, it notes, has not caught up with the “considerable increase in tissue uses for medical research,” and currently deals mainly with organ transplantation.

The HUGO Ethics Committee issued a *Statement on DNA Sampling: Control and Access* (1998) that addresses several ethical issues pertinent to sample collection and sharing in genetic research. Of primary importance is the source of the sample, “that is, whether it was collected during routine medical care or during a specific research protocol since this affects the ambit and the choices available in the consent process.” It bases its specific recommendations concerning the use of stored materials in research on two factors: (1) “the source of the sample, and (2) whether there was, at the time the sample was collected, ‘general notification’ of the institution’s policy concerning future uses of samples.” Of the categories of materials it defines, the HUGO Ethics Committee recommends the most stringent protection for the research use of “routine samples, obtained during medical care and stored . . . before notification of such a policy” (HUGO, 1998). Such samples may be used if, provided there is ethical review, they have
Addressing research conducted in the future, the HUGO Ethics Committee provides recommendations as to what choices should be offered in the consent process. It lists as important information to include in the process the potential uses of the sample and its information. The consent process should also indicate, “whether the sample and its information will: identify the person, code the identity, or anonymize the identity so that the person cannot be traced although some demographic and clinical data may be provided.”

The statement from HUGO is remarkable for its focus on protecting the rights of family members in addition to those of the individual source. It notes as ethical prerequisites “respect for individual values, familial needs and cultural differences as well as the possibility of withdrawal of consent to participate.” Reflecting this focus, it recommends that special considerations be made for access by “immediate relatives” in situations “where there is a high risk of having or transmitting a serious disorder and prevention or treatment is available.”

Finally, its call for international standardization of “ethical requirements for the control and access of DNA samples and information” is a recommendation echoed by other international groups.

In 1998, the three major funding organizations in Canada issued standards and procedures for governing research involving human subjects. In a section devoted to the use of human tissue in research the policy statement addresses issues of privacy and confidentiality, free and informed consent, and the use of previously collected tissue. Elsewhere in this comprehensive document, other concerns raised by human genetic research such as protecting families and biological relatives and the banking of genetic material are discussed.
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

The policy statement distinguishes four categories of tissue: Identifiable (can be immediately linked to a specific individual), traceable (potentially traceable provided there is access to further information such as a patient record or a database), anonymous, and anonymized. It states that the investigator does not need to seek consent, unless applicable law so requires, “When collected tissue has been provided by persons who are not individually identifiable (anonymous and anonymized tissue), and where there are no potential harms to them.” The statement notes that even where it is not possible to identify an individual, the “interests of biological relatives and distinct cultural groups may be adversely affected through research uses of their anonymous tissue.” It states as a requirement that researchers involving families and groups in genetic research reveal potential harms to the ethics board and outline how the harms will be dealt with.

The Canadian policy also addresses how to obtain consent when collecting new material for research. It recommends that potential donors of tissue be informed about, among other things, “the type and amount of tissue to be taken, as well as where the tissue is to be taken; the potential uses for the tissue including any commercial uses; the safeguards to protect the individual’s privacy and confidentiality; and identifying information attached to specific tissue, and its potential traceability.”

The WHO Human Genetics Programme in 1998 issued Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services that devote a section to “Banked DNA.” The purpose of these proposed guidelines is, “to assist policy-makers, officials, practitioners and other health workers in the Member States of WHO in ensuring that genetic information and genetic services are introduced into the broader medical practice of the nations in ethically acceptable ways.”

The WHO proposes that existing stored specimens “should not be subject to new rules
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

for consent or re-contact that may be established in the future.” In the future, “a blanket informed consent that would allow use of a sample for genetic research in general, including future, as yet unspecified projects, appears to be the most efficient and economical approach, avoiding costly re-contact before each new research project.”

Addressing samples to be collected in the future, it recommends a list of issues to consider when policies are developed: Protection of individuals from possible discrimination; Possible benefits to the individual from research findings; The possibility of multiple uses of the same sample in different and unforeseen research projects; Possible sharing among collaborators; Advantages and disadvantages for individuals and researchers of removing all identifiers from a sample.

The WHO’s Guidelines, like those issued by HUGO, discuss the interests that biological relatives have in the control of DNA specimens. It states that “control of DNA may be familial, not only individual” and recommends that “blood relatives may have access to stored DNA for purposes of learning their own genetic status, but not for purposes of learning the donor’s status.”

In sum, these statements reveal that many of the guidelines are based on common ethical considerations such as respect for privacy and confidentiality, respect for autonomy operationalized by a requirement of informed consent, and non-commercialization of human biological materials. There seems to be a common position emerging to the effect that a person’s rights and interests are best protected if that person has some form of control over his or her removed biological material. Nonetheless, there exists a rich diversity of positions on how to control access to and use of human biological materials and the data obtained from them. A greater standardization of policies with regard to the use of DNA samples would certainly facilitate future international cooperation in biomedical research.
Other Considerations: Medical Record Protection and Human Subjects Research

[please note: this section is being revised and updated]

Many protocols calling for research use of human biological materials will also require information from relevant medical records to accompany the tissue. Such information would, as already noted, allow investigators to correlate characteristics of the tissue with characteristics of the etiology and course of the patient’s disease and the patient’s response to various treatments. For this reason, it is not enough for NBAC to study the rules currently governing access to human tissue for research; it must also look at rules governing access to medical records. Where NBAC contemplates changes in the current regime governing tissue research, it will be important to ensure that the changes are compatible with rules and legislation governing access to medical records.

The federal regulations that govern human subjects research apply to the use of medical records. Efforts to link one record with another, or to link a record with an interview of the patient, can be considered “research” under the federal definitions. If the records have any personal identifiers, then this constitutes human subjects research and requires IRB review and patient/subject consent, subject of course to the exceptions outlined above. Indeed, the regulations governing tissue use and medical record use are basically the same and on a practical level treat tissue as simply another form of a medical record.

Currently, no federal law protects the privacy of medical records, unless the records are actually held by the government. Recent legislative movements, however, have sought to address this issue. The passage of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) effectively set a deadline for Congress to act to protect personal privacy. HIPAA required the Secretary of Health and Human Services to make recommendations to Congress, in consultation with the National Committee on Vital and Health Statistics (NCVHS), on ways to
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

protect “individually identifiable” information and to establish penalties for wrongful disclosure of personal health information. The secretary presented those recommendations in September 1997; Congress now has until August 1999 to enact a privacy law. If Congress fails to act, the secretary is directed to promulgate regulations within 42 months of HIPAA enactment (i.e., by February 21, 2000) relating to the privacy of health information transmitted in connection with specified electronic transactions. On August 11, 1998, HHS proposed such regulations, designed to protect the electronic flow of medical data between health care providers, insurers and clearinghouses from improper access or alteration. The proposed regulations and accompanying technical guidance require all parties who deal with electronic health information to establish responsible and appropriate safeguards, develop a security plan, provide training for employees, secure physical access to records and implement a digital signature regimen to verify the identity of the person accessing medical records.

Although the 105th Congress considered several proposals regarding medical privacy legislation, no law was passed during the 1998 session. The major patient protection bills under consideration all contained confidentiality provisions and gave individuals the right to inspect and copy their medical records, except in special circumstances. In addition, several legislative proposals focused exclusively on medical records confidentiality. Such bills differed in their treatment of issues including the appropriate uses of personally identifiable information, whether federal regulations should be applied to both federally and nonfederally funded researchers that use personally identifiable data, and how broad federal preemption of state laws pertaining to confidentiality should be.

With respect to research, the bills differed in both their treatment of federally and

---

12 National Health Policy Forum Issue Brief No.724,p.2.
14 e.g., S.2330, S.1890/H.R. 3605, S.2416, H.R. 4250.
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

privately funded research and in their reliance on the current IRB system. Many of the bills required approval by an IRB for federally funded and nonfederally funded research. One particular bill permitted disclosure to health researchers if the disclosure was “reviewed by a committee, board, or informal organization in accordance with confidentiality standards specifying permissible and impermissible uses of the information.” Another permitted a health researcher to obtain protected health information only under the following circumstances:

(1) from federally funded projects or institutions that have assurances on file with the Office of Protection of Human Subjects at the National Institutes of Health in compliance with rules specified by the federal government; (2) in conformance with rules promulgated by the Food and Drug Administration for new product trials; or (3) if the research is privately funded human subject research.

This particular bill acknowledged that there are currently no specific procedures in place for the third classification of research. It provided for the Senate Committee on Labor and Human Resources to await the recommendations of the secretary of health and human services, after reviewing the commissioned General Accounting Office study on confidentiality and NBAC’s report, to determine appropriate confidentiality procedures for privately funded human subject research.

Finally, the legislative initiatives generally differed on whether to establish a floor or a ceiling for federal standards. Many would have preempted most state laws except those pertaining to mental health and public health activities. Others would not have preempted any state laws that provide a greater level of protection for personally identifiable health information. The latter position is generally consistent with the recommendations presented to Congress by DHHS.

---

16 See S. 1368, H.R. 1815.
17 H.R. 3900.
19 See S.1921, H.R. 52, H.R. 3900.
General statutory and common law rules lay the groundwork in many states for a claim of privacy as against nonconsensual use of medical records. Indeed, nearly every state has laws or regulations that provide varying degrees of protection for information contained within medical records. Recently, states have adopted these statutes most often in the context of protecting the confidentiality of records regarding certain diseases, such as HIV, AIDS, and various mental illnesses. In most instances, these acts are aimed at preventing the use of such personal medical information by insurance companies and employers, and thereby protecting the individual from discrimination and/or stigmatization. The variability of state law protections has been cited as a problem in itself.

Where statutes exist, they may specifically contemplate access to medical records for research use. California’s medical records confidentiality law, for example, states that the “information may be disclosed to public agencies, clinical investigators, health care research organizations, and accredited public or private nonprofit educational or health care institutions for bona fide research purposes. However, no information so disclosed shall be further disclosed by the recipient in any way which would permit identification of the patient.” This section exempts releases of unidentifiable medical information for bona fide research purposes from the law’s general requirement of patient authorization for any release.

The California law defines “medical information” as “any individually identifiable information in possession of or derived from a provider of health care regarding a patient’s

---

20 S. 1368, H.R. 1815.
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

medical history, mental or physical condition, or treatment,”31 language which is very similar to that of the Common Rule. Finally, it is interesting to note that California separately addresses disclosure of genetic test results contained in an “applicant or enrollee’s medical records” by a health care service plan. The law forbids disclosure by a health care service plan of “results of a test for a genetic characteristic to any third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization.”28

Florida and Minnesota laws also specifically address the use of medical records in research. Florida’s general medical record confidentiality statute states that records “may not be furnished to, and the medical condition of a patient may not be discussed with, any person other than the patient or the patient’s legal representative or other health care practitioners and providers involved in the care or treatment of the patient, except upon written authorization of the patient.”32 However, as in California, such records may be furnished without written authorization “[f]or statistical and scientific research, provided the information is abstracted in such a way as to protect the identity of the patient or provided written permission is received from the patient or the patient’s legal representative.”33

In Minnesota,

[a] provider, or a person who receives health records from a provider, may not release a patient’s health records to a person without a signed and dated consent from the patient or the patient’s legally authorized representative authorizing the release, unless the release is specifically authorized by law. . . . [A] consent is valid for one year or for a lesser period specified in the consent or for a different period provided by law.34

27 Id. § 56.05(b).
28 Id. § 56.17.
30 Id, § 455.667(5)(d).
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

An exception to Minnesota’s general rule is that health records “may be released to an external researcher solely for purposes of medical or scientific research.” The State allows the release of health records generated before January 1, 1997 if the patient has not objected or does not elect to object after that date; in contrast, the State requires that, for health records generated on or after January 1, 1997, the provider must:

(i) disclose in writing to patients currently being treated by the provider that health records, regardless of when generated, may be released and that the patient may object, in which case the records will not be released; and

(ii) use reasonable efforts to obtain the patient’s written general authorization that describes the release of records in item (i), which does not expire but may be revoked or limited in writing at any time by the patient or the patient’s authorized representative.

Further, in making a release for research purposes, the provider must make a reasonable effort to determine that:

(i) the use or disclosure does not violate any limitations under which the record was collected;

(ii) the use or disclosure in individually identifiable form is necessary to accomplish the research or statistical purpose for which the use or disclosure is to be made;

(iii) the recipient has established and maintains adequate safeguards to protect the records from unauthorized disclosure, including a procedure for removal or destruction of information that identifies the patient; and

(iv) further use or release of the records in individually identifiable form to a person other than the patient without the patient’s consent is

31 Minn. Stat. § 144.335 subdivision 3a (1997).
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

In addition to existing statutes, there has been a recent proliferation of state legislative initiatives addressing the use of medical information. Many of these initiatives attempt to protect an individual’s privacy interest by preventing the dissemination of personal information—doing so by restricting the ability of those who hold medical records, such as hospital pathology laboratories, to give out information from the records, and by restricting the ability of investigators to conduct such research except in certain circumstances.

According to many of the pending initiatives, when a researcher who uses human biological material requests additional information about the source of a sample, the record holder may have a legal obligation not to disclose that information. Primarily, information from medical records can be disclosed only if one of two conditions is fulfilled: either the patient (or the patient’s legally authorized representative) gives a specific, written consent that information from his or her medical record can be released in the circumstances at hand, or the information that is requested and released will not permit identification of the individual. Exactly what constitutes identifying information is oftentimes not defined by the legislative initiatives and also varies from state to state. Several bills provide a civil action for negligent release of personal information without consent or for violation of the bills’ confidentiality requirements.

Finally, many legislative initiatives prohibit research facilities from obtaining or retaining samples for genetic testing unless the source has given consent or the sample is used in anonymous research. A few states are considering bills that provide the source of the sample with greater control over its uses by giving the source a legal property right in the sample and information that is derived therefrom. To date only one state has passed such a provision into law, and the property right it grants does not address the source’s ability to profit monetarily.

What appears clear from the state legislative initiatives is that there is a perceived need to protect medical information, especially information that can be linked to an individual, from the possible negative consequences of research conducted on human biological materials and personal information derived from such materials.

Courts themselves have only recently begun to recognize individual “privacy” rights with respect to one’s medical records. Early cases viewed unauthorized disclosure as a form of breach of statutory duty, libel, malpractice, breach of trust, or breach of contract. The language in one New York case from that era is quite strong in its condemnation of what it deemed a valid claim for unauthorized revelation of medical secrets: "Despite the fact that in no New York case has such a wrong been remedied, due most likely to the fact that so few physicians violate this fundamental obligation, it is time that the obligation not only be recognized but that the right of redress be recognized as well." Similarly, the United States Court of Appeals for the Third Circuit tentatively recognized a form of a privacy right against the government’s request for access to medical records in order to investigate alleged health hazards. The court balanced this “right” against seven factors: "the type of record requested, the information it does or might contain, the potential for harm in any subsequent nonconsensual disclosure, the injury from disclosure to the relationship in which the record was generated, the adequacy of safeguards to prevent unauthorized disclosure, the degree of need for access, and whether there is an express statutory mandate, articulated public policy, or other recognizable public interest militating toward access." In that particular case, the court held that "the public need prevailed over the claim that medical records in general were protected from discovery." Of course, it is not necessarily true that all courts conducting this type of analysis would grant investigators access to

33 See e.g., 1998 UT H.B. 271; 1997 MI H.B. 5459.
34 See Oregon’ s statute addressing an individual’ s rights in genetic information, ORS @ 659.715 (1997).
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

medical records despite asserted privacy rights.

More recently, the Second Circuit found that an individual has a constitutional right to privacy in his HIV status because his personal medical condition is a matter that he is normally entitled to keep private. Again, it is unclear how this would apply in a medical research setting, but it is significant for its explicit reliance on constitutional levels of protection for one’s right to keep medical information private. Finally, some state constitutions offer additional various types of privacy protection.

Summary

In its deliberations, NBAC reviewed the applicability of the existing federal regulations pertaining to research with human biological materials and identified some notable ambiguities. First, the current regulations do not make completely clear what is meant by “identifiability” when determining whether in fact a human subject is involved in research on biological samples. Thus, there is resulting confusion about just how certain types of research relate to existing federal regulations and requirements (based on how closely the samples are linked to their sources and how easily that linkage can be accomplished). The issue of identifiability is further confounded by the researcher’s growing ability to identify the source (even when ostensibly unidentified) because of the uniqueness of the clinical information that accompanies the material when it is delivered from the repository. The confusion about identifiability has implications for the harms that might occur and the consent that might be required.

April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

In addition, scientific and medical groups vary in the way they define the identifiability of samples and the protections recommended for each category. Several have developed guidelines for IRBs and investigators as they confront the questions that arise when research is proposed using existing materials. These statements contain some but not explicit discussion about the mechanisms for ensuring the materials are stored and/or used in such a way that the confidentiality of the source of the material is promoted.

Moreover, the current federal regulations are silent on the topic of group or community harm. Thus, protocols that pose insignificant risks to individuals but might implicate strong group interests do not get special IRB attention. This has implications for groups such as kindreds or ethnic and racial subpopulations as well as collectivities of individuals who share a common trait, such as a genetic condition or disease status.

In addition, the regulations offer insufficient guidance on the meaning of “minimal” risk or the nature of the subjects’ “rights and welfare” to be protected. The existing regulations also do not make clear the status of living relatives of deceased individuals whose stored samples are used in research. Although OPRR has indicated that these people might in fact be considered human subjects by virtue of their genetic relationship to the sample source, the regulations do not specify how this consideration is to be handled by IRBs.

Finally, there are major unresolved issues pertaining to the on-going access to medical records that have significant implications for research using human biological materials.

Despite the fact that the current regulations appear to apply in most cases, other issues pertaining to adequate protections arise. For example, provision of informed consent is a required but insufficient protection of both the interests of the research subject and the investigator. Moreover, there might be overriding state laws that apply regarding the research use of medical records, thereby limiting the ability of researchers to gather unlimited information from
April 1, 1999: This is a draft report of the National Bioethics Advisory Commission. It therefore does not reflect final conclusions or recommendations of NBAC and should not be cited or referenced as such.

1 individuals whose names are linked to the biological material.

2

3 The next chapter addresses the ethical issues that should be considered when devising a strategy for review and conduct of research using human biological materials.
Chapter 3 References


